Objectives: Leptin and Endothelin (ET) as important endogenous factors interact with each other which may contribute to a better understanding their role in diabetic pathogenesis.
INTRODUCTION
Diabetes Mellitus (DM) is the most common endocrine and metabolic disorder of our age, emerging as a result of real or functional lack of insulin, which is characterized by blood, carbohydrate, protein and fat metabolism disorder (1-3).
Today, experimental diabetes models can be formed with various materials and methods. One of the ingredients used to create an experimental diabetes model is streptozotocin (STZ). Diabetes created with STZ is a commonly used model in terms of formation of insulin dependent diabetes model of human (4).
ET's are the peptides occurring naturally in many cell types of the body and known as the most potent vasoconstrictor molecules (5, 6) . There are ET isopeptides in humans and other mammals, named as ET-1, ET-2 and ET-3 which have different structural and pharmacological effects. ET-1 is the primarily ET which is synthesized by endothelial cells (7) . It shows paracrine and autocrine effects via ET A R and ET B R on the endothelial and smooth muscle cells (8) . There are many studies that have demonstrated the increase in the level of ET-1 in diabetes (9, 10) . ET-1 also leads to the progression of DM (11).
Leptin is a protein hormone, that derives its name from the Greek word leptos, which means thin, produced by ob-gene in fat cells and other tissues and released to plasma (12, 13) .
Insulin is the most researched Leptin-associated hormone and an important regulator of the ob-gene expression (14) . Leptin and other adipocytokines were associated with the type 2 DM and insulin resistance (15) . It has been demonstrated that Leptin deficiency lead to severe insulin resistance in uncontrolled DM (16) . Additionally, it has been informed that Leptin had an anti-diabetic effect in diabetic rats. Researches has been shown that Leptin had powerful anti-diabetic effect in the STZ-induced insulin dependent diabetic rats and transgenetic mice (17) .
There are some studies evaluating the relationship between Leptin and ET-1 in different diseases and systems. For example, ET-1 stimulates Leptin production with ET A R in adipocyte cultures (18) . In another study conducted by Juan et al., Leptin increased the levels of ET A R in vascular smooth muscle cells (19) . It has been informed that, Leptin induced ET-1 in endothelial cells (20) . These data suggest that increased ET-1 levels in diabetes due to the relationship between Leptin and ET-1, may affect the plasma Leptin levels.
Although there are many studies evaluating as well as Leptin and ET-1 separately in various diseases and systems, any study that demonstrates how ET-1 and Leptin affect each other in diabetes and how ET receptor antagonists affect plasma Leptin levels in diabetes, could not find. Therefore, we aimed to investigate the effects of ET A R antagonist BQ-123 on Leptin levels in STZ-diabetic rats.
The studies demonstrate that a decrease in Leptin levels may occur in STZ-induced diabetic rats. How this decrease affects in diabetic rats given ET A R antagonist BQ-123 became our scientific curiosity. Because, there are some studies demonstrating increase in ET-1 and endothelium caused up-regulation of Leptin secretion levels in diabetes.
Hence, Leptin levels which were already decreased in diabetes may be reduced more with the application of ET receptor antagonist. It is known that, decrease in Leptin levels in diabetes caused adverse effects. So, it should be determined that how ET A R antagonist affected the increased levels of Leptin in diabetes.
SUBJECTS AND METHODS
Before the experiment, the approval was taken from Gaziosmanpasa University Local Ethics Committee for Animal Experiments and animal rights were protected (2010-HADYEK-029).
In the experiment, 24 male Wistar albino rats weighting 180-250 g were used. Rats were kept in cages at room temperature 21±2 ºC with a 12 h light/dark cycle, fed with standard rat pellet food and tap water.
Chemicals
STZ and BQ-123 were obtained from Sigma Chemical Co., (St. Louis, MO). STZ was dissolved in cold phosphate-citrate buffer solution (0.1 M, pH=4.5). Buffer solution was prepared freshly and protected from light. BQ-123 dissolved in0.9 % NaCl.
Procedure for diabetes
Rats were randomly divided into 3 groups and each group included 8 rats (Control group, n=8, STZ group n=8, STZ+BQ-123 group n=8). Blood-glucose levels of the each rat, fasted for 12 h, were measured with a sugar measuring instrument (glucometer) (PlusMED ACCURO pM1300) and recorded. After that, by measuring the weight of each rats, STZ 60 mg/kg, which was prepared freshly by dissolving in phosphate-citrate buffer (pH=4.5), was administered i.p. to the rats in STZ and STZ+BQ-123 groups. For the control group, phosphate-citrate buffer with the same volume was administered i.p. Then, the feeding of rats was released. Fasting blood glucose levels were measured again 72 h after the STZ administration, the rats with the level of 200 mg/dl or higher were considered as diabetic. In order to complete the formation of diabetic physiopathology, rats were kept under the appropriate conditions for 40 days after the STZ implementation. The diabetes procedure was prepared with the reference of few studies that have been done before (21, 22) .
Treatment procedure
The rats in STZ+BQ-123, STZ group, 39th and 40th days after the application, (2 mg/kg+2mg/kg), a total of 4mg/kgBQ-123 was administered i.v. from tail vein. For the rats in control and STZ group, instead of BQ-123, same volume of saline was given. Rats were sacrificed by taking 4-5 ml cardiac blood samples under anesthesia with, Ketamine (30 mg/kg) and xylazine (5 mg/kg) 6 hours after the last BQ-123 implementation.
The Measurement of plasma leptin
Leptin levels were measured in the plasma obtained after centrifugation of blood by using the method of Enzyme-Linked Immunosorbent Assay (ELISA). The Mouse / Rat ELISA Leptin kit (Biovendor, Cat no: RD291001200R, North Carolina, USA) was used for determination of 
Measurement of serum TBARS levels
Serum TBARS levels were measured by Mihara and Uchiyama method. In this, in TBA test reaction, malondialdehyde (MDA) or MDA-like substances produce a pink color by entering reaction with TBA and give the maximum absorbance at 532 nm. The reaction was carried out at 90 ºC and at pH = 2-3 for 15 min. In order to bring down the proteins, the samples were stirred with two-fold volume of 10% cold trichloroacetic acid (w/v). The particles were brought down by centrifugation and the reaction of liquid part of the supernatant and equal volume of 0.67% of (w/v) TBA was performed in boiling water bath for 10 minutes. After cooling, it was read with the spectrophotometer at 532 nm. The results were calculated as nmol/ml (24) .
Measurement of the level of serum PC
Detection of protein carbonyl groups; was performed on the basis of the spectrophotometrically measurement of stable hydrazone compounds formed as a results of reaction of protein carbonyl groups with 2,4-dinitrophenyl hydrazine at 370 nm. During calculations, Ɛ =22000 M-1 cm-1 was accepted as molar absorption coefficient at 370 nm for 2.4 dinitrophenyl hydrazine. Protein carbonyl levels were calculated as nmol/ml (25) .
Measurement of serum NO Level
Amount of nitrite in the serum was determined by the Griess reaction after deproteinization.
Total nitrite (nitrite + nitrate) was evaluated with the modified cadmium reduction method.
Nitrate reduction was provided at the end of the 90-minute incubation with copper (Cu)-coated cadmium granules deproteinized sample supernatant in pH 9.7 glycine buffer.
Produced nitrites; were determined with sulfanilamide and related N-naphtylethylenediamine (NNDA) diazotization. A pink color occurred as a result of the reaction was read with the help of spectrophotometer at a wavelength of 545 nm. Nitrate concentration was determined by substracting the resulting concentration from the first concentration (26) .
Other biochemical analyses
Plasma Na, K, Cl values were measured with the help of an auto analyzer (Cobas C 501, Tokyo, JAPAN) by using indirect Na + , K + , Cl -kits.
Statistical analysis
Statistical analysis was performed with "SPSS 19.0 for Windows". For the comparison of the differences between the groups, "One-way ANOVA" test was used. In which case the data did not comply with the normal distribution (p≤0.05 according to the Levene test), instead of this test, "Kruskal-Wallis Analysis of Variance" was applied. When the differences between groups were found significant in one-way analysis of variance (p≤0.05), the groups were compared in pairs with "Tukey HSD" which is one of the Post Hoc tests. When the differences between groups were found significant in Kruskal-Wallis Analysis of Variance (p≤0.05), the groups were compared in pairs with "Mann-Whitney U test (Bonferroni correction)". Results were expressed as mean ± standard deviation.
RESULTS

Live Body Weights of Rats during the Test
The weights of the rats were measured at the beginning, in the middle and at the end of the experiment, they were recorded as; for the control group; 184.37±12. 37, 193 and STZ + BQ-123 group (p=0.015) were significantly lower than the control group. Diabetic rats lost weight.
Fasting Blood Glucose Levels in Rats during the Test
The fasting blood-glucose levels of the rats compared on the basis of the groups, no significant difference was found between the groups at the beginning of the experiment (p=0.384). In the measurements performed 72 hours after the application of STZ, the blood glucose levels of rats in control, STZ and STZ+BQ-123 groups were recorded as 127.00±15.32, 491.75 ± 72.65, 501.13 ± 75.75 mg/dl, respectively. The blood glucose levels of the rats in STZ and STZ + BQ-123 groups were found significantly higher than the levels of the control group (for both p=0.0001). An experimental diabetes model was achieved in rats with STZ.
Plasma Levels of Leptin, Serum Levels of PC, TBARS, NO
The plasma Leptin levels of the rats in the experimental groups were, in the control 0.92 ± 0.58 ng/ml, in STZ group; 0.58 ± 0.34 ng/ml, STZ+BQ-123 group; 0.38±0.29 ng/ml. Leptin levels were analyzed according to the groups, but no significant difference was found (p=0.055) ( Table 1 ; Figure 1 ). Figure 4 ).
Other biochemical parameters
The serum Na + concentration levels were measured in control, STZ and STZ+BQ-123 were 
DISCUSSION
In our study, the blood glucose levels of STZ and STZ + BQ-123 groups measured 72 hour after STZ application were significantly higher than the values of the control group. This finding supports that, model of diabetes was successful, and 60 mg/kg dose of STZ was sufficient. In the rats that diabetes was formed after administration of STZ, during the test, for a period of 40 days, polyphagia, polydipsia, polyuria, and hyperglycemia was observed. These findings observed in diabetic rats were consistent with the clinical signs of diabetes.
Hypoleptinemia accompanies to hyperglycemia observing due to reduced insulin secretion which occurs due to the destruction of the pancreas with the effect of STZ in this model (27, 28 ). Previous studies demonstrate that, serum Leptin levels decreased in diabetes (27, 29) . Studies in STZ-diabetic rats have indicated that the levels of serum Leptin and
Leptin mRNA noticeably diminished (28). The levels of plasma Leptin also decreased in
Type II DM patients (30) and in Type I DM patients (31). In our study, although Leptin levels in STZ group were lower than the control group, this was not statistically significant (p = 0.055). Despite the decrease in Leptin levels in diabetic groups, the reason that we did not find significantly difference may be related with STZ dose and duration.
ET-1 biosynthesis increases in diabetes, and therefore this peptide causes vascular complications. There are some studies that have shown an increase in ET-1 levels in diabetes.
For example, in a study conducted by Makino and Kamatoin STZ-diabetic rats, as well as the formation of hyperglycemia, ET-1 levels were found increased significantly in STZ-diabetic rats (9) . DM is a chronic metabolic disorder and at the same time as an increased oxidative stress situation (32). Oxidative stress acts as a leading factor in DM and its complications (33, 34).
Several studies inform that free radicals and reactive oxygen species increased in DM rats and patients (34-38). Lipid peroxidation occurring due to free oxygen radicals is one of the most important causes of cell damage. Lipid peroxidation is defined as a chemical event initiated
by free radicals and contains the oxidation of unsaturated fatty acids of membrane structure (Turk et al., 2002) . TBARS, produced endogenously in the body, is an important indicator of lipid peroxidation (39) and the studies indicate that tissue and plasma TBARS levels increased in diabetes. In our study, in the serum of STZ-diabetic rats, TBARS levels which are an indicator of lipid peroxidation, were increased significantly compared with control group.
This increase in lipid peroxidation in diabetic rats is similar to other studies on diabetic rats and humans. In a study conducted by Turk et al., a significant increase of TBARS levels in patients with Type 2 DM has been reported (40) . In another study conducted by Ruberz et al.,
it has been detected that, plasma TBARS levels in STZ-diabetic rats were significantly higher than the control group (41) . In another study conducted by Jeyashanthi et al., an increase in serum, liver and kidney tissues levels of TBARS of STZ-diabetic rats was detected (42) . Our study is in line with these data.
Researchers have used various agents against DM such as melatonin (43) (44) (45) (46) . We used BQ-123 that is a selective ET A R antagonist and decreases ET-1 levels in serum (47) .
Although the effect of BQ-123 on TBARS levels was investigated, we did not find any study about how BQ-123 affects the increased levels of TBARS in diabetes. However, in renal ischemia and reperfusion injury, BQ-123 has as the effects of antioxidant, decreased the increased levels of TBARS (48) . In another study conducted by Lund et al., it has been determined that, BQ-123 reduced cardiac TBARS levels (49). BQ-123 as an ET A R antagonist inhibited the formation of lipid and protein oxidation products (50). Our results are in line with these studies. In the group treated with BQ-123, levels of TBARS showed a significant decrease compared with STZ group. In our study, it can be said that, BQ-123 has a positive effect by reducing the increased levels of TBARS in diabetes.
It has been reported that there is a significant protein oxidation caused by oxidative damage in diabetic patients (22) and diabetic rats (51) . In our study, there was no significant difference between the groups in terms of serum PC levels. To keep longer duration of diabetes and examination on tissue samples may help to show the change in the levels of PC.
In our study, due to checking only serum PC levels, in 40-day period, protein damage may not be reflected in the serum levels.
NO, was produced enzymatically by nitric oxide synthetase (NOS) from L-arginine (52) . It has been reported that, in diabetes, bioactivity of NO, basal NO production and Larginine which is a NOS substrate decreased, and some researchers indicate that, in diabetes, NO production has been damaged due to decrease in the plasma levels of L-arginine (53).
Decreased levels of NO, contributes the vascular damage, by facilitating interactions of platelet-vascular wall and causing adhesion of circulating monocytes to endothelial surface (54) . Therefore, it is important to keep the NO levels in the physiological limits. In our study, in terms of NO levels, there is significant difference between the values of control and STZ groups. A significant reduction in NO levels occurred in diabetic rats. The studies indicate that, NO levels decrease in diabetes. In another study conducted by Zhao et al., it has been determined that, expression of eNOS decreased in the aortas of STZ-diabetic rats (55) .In the study conducted by Tessari et al. on diabetic patients, it has been reported that, concentrations of NO significantly decreased in the blood of diabetic patients (56) . Our study is in line with these data. In our study, NO levels of rats in STZ and STZ + BQ-123 group decreased significantly compared to control rats, and the effect of BQ-123 which increases the level of NO was not detected. 
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